AKTS
Aktis OncologyANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Aktis is advancing two clinical-stage radiopharmaceutical programs, with AKY-2519 now in Phase 1b and AKY-1189 enrolling across multiple Nectin-4-expressing tumor types. Successful trial execution and credible 2027 preliminary data could support substantial re-rating.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.3.
What can break
Clinical data may fail to demonstrate sufficient efficacy, safety, dosimetry, or target engagement.
Momentum
97
Value
46
Sentiment
61
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $29.00 · Bull $40.00 · Bear $17.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $34.38
Why
Momentum97 · Δ7d -1.3
Value46 · Δ7d 0.0
Sentiment61 · Δ7d +7.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
97
26% active weight
Current posture
7d trendSoftening
Δ7d
-1.3
Δ21d
+3.3
Value
46
39% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.7
Sentiment
61
34% active weight
Current posture
7d trendImproving
Δ7d
+7.3
Δ21d
+8.4
Why this grade
Composite grade A. Momentum 97.1 / Value 46.4 / Sentiment 61.1
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.38B
Beta
-
Shares Out
55.28M
P/E (TTM) · Derived
-20.9
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
+123.0%
EPS YoY
+18.1%
Gross Margin
-
Op Margin
-
Net Debt
-$215.24M
Current Ratio
19.49
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology